Form 4: 10x Genomics CEO Serge Saxonov Reports Stock Transactions

10x Genomics CEO Serge Saxonov sold 6,693 shares of Class A Common Stock to cover tax obligations and received 1,850 shares as a gift.

Summary

• Serge Saxonov, CEO of 10x Genomics, engaged in stock transactions involving Class A Common Stock.
• On November 21, 2024, Saxonov received 1,850 shares as a gift.
• On November 22, 2024, Saxonov sold 6,693 shares at a price of $13.6878 per share.
• The sale was to cover tax withholding obligations related to the vesting of restricted stock units.
• Following these transactions, Saxonov directly owns 872,574 shares of Class A Common Stock.
• Saxonov also indirectly owns shares through various trusts: 27 shares through the Andromeda Trust, 870 shares through the Sirius Trust, 213,250 shares through the Y/S Descendants' Trust, and 22,570 shares through the Y/S Pot Trust.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing detailing stock transactions by an executive. It doesn't indicate any positive or negative sentiment, it is a neutral event.

Industry Context

This is a routine filing related to insider trading activity, which is common for executives of publicly traded companies. It provides transparency into the transactions of company leadership.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, and this filing is consistent with those requirements.
• The transactions are typical for executives who receive stock-based compensation and need to cover tax obligations.

Stakeholder Impact

• The stock sale by the CEO may have a minor impact on the stock price, but it is a common occurrence and unlikely to cause significant fluctuations.

Key Dates

Keywords

10x Genomics, Serge Saxonov, stock transaction, Class A Common Stock, SEC Form 4, insider trading, restricted stock units, tax withholding